Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)

Carlo Lazzaro, Riccardo Bartoletti, Giorgio Guazzoni, Fausto Orestano, Giovanni L. Pappagallo, Domenico Prezioso, Filiberto Zattoni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The paper compares costs and Quality-Adjusted Life Years (QALYs) of differ ent hormonal therapies (HTs) administered to 275 out of 471 patients with prostate can cer (PC) enrolled in the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS), who did not change HT during the study period. Methods: QALYs and costs related to monoHT with: cyproterone acetate (CYP) (42 patients); bicalutamide (BIC) (41 patients); LHRH-a (96 patients) and complete androgenic block ade (CAB) with: CYP (CYP CAB) (50 patients); BIC (BIC CAB) (46 patients) were compared via a cost-utility analysis (CUA) adopting the Italian National Healthcare Service (INHS) viewpoint. Results: As no statistical significant difference among the mean QALYs gained with the different HTs was detected (p = 0.116), CUA was replaced by a cost minimization analysis (CMA). However, the lowest and the highest mean QALYs gained per patient were registered for BIC CAB (0.59; 95% CI: 0.50; 0.68) and for for CYP (0.75; 95% CI: 0.68; 0.82), respectively. CYP was the least costly HT, reaching the lowest and the highest savings when compared to LHRH-a (-Euros 974.99; 95% CI: -Euros 1066.86; -Euros 883.12; p

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalArchivio Italiano di Urologia e Andrologia
Volume79
Issue number3
Publication statusPublished - Sep 2007

Fingerprint

Androgen Antagonists
Cyproterone Acetate
Cost-Benefit Analysis
Observational Studies
Prostatic Neoplasms
Quality of Life
Quality-Adjusted Life Years
Costs and Cost Analysis
Gonadotropin-Releasing Hormone
Therapeutics
Prostate
Delivery of Health Care
bicalutamide

Keywords

  • Cost-minimization analysis
  • Cyproterone acetate
  • Prostate cancer
  • QuABIOS

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS). / Lazzaro, Carlo; Bartoletti, Riccardo; Guazzoni, Giorgio; Orestano, Fausto; Pappagallo, Giovanni L.; Prezioso, Domenico; Zattoni, Filiberto.

In: Archivio Italiano di Urologia e Andrologia, Vol. 79, No. 3, 09.2007, p. 104-107.

Research output: Contribution to journalArticle

Lazzaro, Carlo ; Bartoletti, Riccardo ; Guazzoni, Giorgio ; Orestano, Fausto ; Pappagallo, Giovanni L. ; Prezioso, Domenico ; Zattoni, Filiberto. / Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS). In: Archivio Italiano di Urologia e Andrologia. 2007 ; Vol. 79, No. 3. pp. 104-107.
@article{ca90461eceeb457788e5cfdc081cf31f,
title = "Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)",
abstract = "Objective: The paper compares costs and Quality-Adjusted Life Years (QALYs) of differ ent hormonal therapies (HTs) administered to 275 out of 471 patients with prostate can cer (PC) enrolled in the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS), who did not change HT during the study period. Methods: QALYs and costs related to monoHT with: cyproterone acetate (CYP) (42 patients); bicalutamide (BIC) (41 patients); LHRH-a (96 patients) and complete androgenic block ade (CAB) with: CYP (CYP CAB) (50 patients); BIC (BIC CAB) (46 patients) were compared via a cost-utility analysis (CUA) adopting the Italian National Healthcare Service (INHS) viewpoint. Results: As no statistical significant difference among the mean QALYs gained with the different HTs was detected (p = 0.116), CUA was replaced by a cost minimization analysis (CMA). However, the lowest and the highest mean QALYs gained per patient were registered for BIC CAB (0.59; 95{\%} CI: 0.50; 0.68) and for for CYP (0.75; 95{\%} CI: 0.68; 0.82), respectively. CYP was the least costly HT, reaching the lowest and the highest savings when compared to LHRH-a (-Euros 974.99; 95{\%} CI: -Euros 1066.86; -Euros 883.12; p",
keywords = "Cost-minimization analysis, Cyproterone acetate, Prostate cancer, QuABIOS",
author = "Carlo Lazzaro and Riccardo Bartoletti and Giorgio Guazzoni and Fausto Orestano and Pappagallo, {Giovanni L.} and Domenico Prezioso and Filiberto Zattoni",
year = "2007",
month = "9",
language = "English",
volume = "79",
pages = "104--107",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "3",

}

TY - JOUR

T1 - Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)

AU - Lazzaro, Carlo

AU - Bartoletti, Riccardo

AU - Guazzoni, Giorgio

AU - Orestano, Fausto

AU - Pappagallo, Giovanni L.

AU - Prezioso, Domenico

AU - Zattoni, Filiberto

PY - 2007/9

Y1 - 2007/9

N2 - Objective: The paper compares costs and Quality-Adjusted Life Years (QALYs) of differ ent hormonal therapies (HTs) administered to 275 out of 471 patients with prostate can cer (PC) enrolled in the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS), who did not change HT during the study period. Methods: QALYs and costs related to monoHT with: cyproterone acetate (CYP) (42 patients); bicalutamide (BIC) (41 patients); LHRH-a (96 patients) and complete androgenic block ade (CAB) with: CYP (CYP CAB) (50 patients); BIC (BIC CAB) (46 patients) were compared via a cost-utility analysis (CUA) adopting the Italian National Healthcare Service (INHS) viewpoint. Results: As no statistical significant difference among the mean QALYs gained with the different HTs was detected (p = 0.116), CUA was replaced by a cost minimization analysis (CMA). However, the lowest and the highest mean QALYs gained per patient were registered for BIC CAB (0.59; 95% CI: 0.50; 0.68) and for for CYP (0.75; 95% CI: 0.68; 0.82), respectively. CYP was the least costly HT, reaching the lowest and the highest savings when compared to LHRH-a (-Euros 974.99; 95% CI: -Euros 1066.86; -Euros 883.12; p

AB - Objective: The paper compares costs and Quality-Adjusted Life Years (QALYs) of differ ent hormonal therapies (HTs) administered to 275 out of 471 patients with prostate can cer (PC) enrolled in the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS), who did not change HT during the study period. Methods: QALYs and costs related to monoHT with: cyproterone acetate (CYP) (42 patients); bicalutamide (BIC) (41 patients); LHRH-a (96 patients) and complete androgenic block ade (CAB) with: CYP (CYP CAB) (50 patients); BIC (BIC CAB) (46 patients) were compared via a cost-utility analysis (CUA) adopting the Italian National Healthcare Service (INHS) viewpoint. Results: As no statistical significant difference among the mean QALYs gained with the different HTs was detected (p = 0.116), CUA was replaced by a cost minimization analysis (CMA). However, the lowest and the highest mean QALYs gained per patient were registered for BIC CAB (0.59; 95% CI: 0.50; 0.68) and for for CYP (0.75; 95% CI: 0.68; 0.82), respectively. CYP was the least costly HT, reaching the lowest and the highest savings when compared to LHRH-a (-Euros 974.99; 95% CI: -Euros 1066.86; -Euros 883.12; p

KW - Cost-minimization analysis

KW - Cyproterone acetate

KW - Prostate cancer

KW - QuABIOS

UR - http://www.scopus.com/inward/record.url?scp=35948994544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948994544&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 104

EP - 107

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 3

ER -